These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ahmad NM; Rojtman AD Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160 [TBL] [Abstract][Full Text] [Related]
10. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A; Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324 [TBL] [Abstract][Full Text] [Related]
11. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Steinkraus G; White R; Friedrich L J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693 [TBL] [Abstract][Full Text] [Related]
12. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793 [TBL] [Abstract][Full Text] [Related]
13. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222 [TBL] [Abstract][Full Text] [Related]
14. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Moise-Broder PA; Sakoulas G; Eliopoulos GM; Schentag JJ; Forrest A; Moellering RC Clin Infect Dis; 2004 Jun; 38(12):1700-5. PubMed ID: 15227615 [TBL] [Abstract][Full Text] [Related]
15. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? Sakoulas G; Eliopoulos GM; Moellering RC; Novick RP; Venkataraman L; Wennersten C; DeGirolami PC; Schwaber MJ; Gold HS J Infect Dis; 2003 Mar; 187(6):929-38. PubMed ID: 12660939 [TBL] [Abstract][Full Text] [Related]
16. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350 [TBL] [Abstract][Full Text] [Related]
17. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Tsuji BT; Harigaya Y; Lesse AJ; Sakoulas G; Mylotte JM Diagn Microbiol Infect Dis; 2009 Jun; 64(2):220-4. PubMed ID: 19345040 [TBL] [Abstract][Full Text] [Related]
18. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. Hussain FM; Boyle-Vavra S; Shete PB; Daum RS J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353 [TBL] [Abstract][Full Text] [Related]
19. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Lodise TP; Miller CD; Graves J; Evans A; Graffunder E; Helmecke M; Stellrecht K J Antimicrob Chemother; 2008 Nov; 62(5):1138-41. PubMed ID: 18694905 [TBL] [Abstract][Full Text] [Related]
20. Key considerations in the treatment of complicated staphylococcal infections. Jones RN Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]